Literature DB >> 9409269

A prothrombin gene mutation is significantly associated with venous thrombosis.

R K Kapur1, L A Mills, S G Spitzer, M B Hultin.   

Abstract

This case-control study examined the prevalence of a prothrombin gene mutation in the 3'-untranslated region (UTR) first reported by Poort et al in Dutch subjects with a history of venous thrombosis and in matched control subjects without a history of thrombosis. We tested the hypothesis that the presence of the 3'UTR prothrombin mutation would convey a higher risk of venous or arterial thrombosis and therefore would be found in a higher-than-normal percentage of subjects with a history of thrombosis. Our study included 100 subjects: 50 with a history of thrombosis (21 with venous thrombosis and 29 with arterial thrombosis, who had been recruited from an anticoagulation clinic) and 50 control subjects without a history of thrombosis. DNA from these subjects was analyzed by polymerase chain reaction and agarose gel electrophoresis. We found a statistically significant increase in the prevalence of the 3'UTR mutation in subjects with a history of venous thrombosis compared with subjects without thrombosis. The prevalence of the 3'UTR prothrombin mutation was 19% (4/21;3 heterozygous and 1 homozygous) in subjects with a history of venous thrombosis, 0% (0/29) in subjects with a history of arterial thrombosis, and 2% (1/50) in control subjects (P < .0245, by Fisher's exact test for comparison of subjects with versus those without a history of venous thrombosis). The G-->A mutation at nucleotide 20,210 in the 3'UTR was confirmed by direct DNA sequencing. The similar increased prevalence of the 3'UTR mutation in subjects with venous thrombosis in our population and in the Dutch population studied by Poort et al suggests that this mutation is an important risk factor for venous thrombosis in the general white population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409269     DOI: 10.1161/01.atv.17.11.2875

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

Review 1.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

Review 2.  Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David Bosler; Joan Mattson; Domnita Crisan
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

3.  Association of C677T MTHFR and G20210A FII prothrombin polymorphisms with susceptibility to myocardial infarction.

Authors:  Wiam Hmimech; Hind Hassani Idrissi; Brehima Diakite; Dalila Baghdadi; Farah Korchi; Rachida Habbal; Sellama Nadifi
Journal:  Biomed Rep       Date:  2016-07-13

4.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

5.  Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity.

Authors:  Samantha Schockman; Charles J Glueck; Robert K Hutchins; Jaykumar Patel; Parth Shah; Ping Wang
Journal:  Clin Ophthalmol       Date:  2015-04-03

6.  Factor VLeiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease.

Authors:  Bahadir Ercan; Lülüfer Tamer; Nehir Sucu; Hasan Pekdemir; Ahmet Camsari; Uğur Atik
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.